The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES).
 
Johann De Bono
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Acai Therapeutics; Amgen; Amunix (Inst); Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric; Crescendo Biologics (Inst); Daiichi Sankyo; Dark Blue Therapeutics (Inst); Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon therapeutics; ImCheck therapeutics; Immunic Therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; MetaCurUm; Myricx Pharma; Novartis; Nurix (Inst); Oncternal Therapeutics; Orion; Pfizer (Inst); Qiagen; Sanofi Aventis GmbH (Inst); Sierra Oncology; Taiho Oncology; Takeda (Inst); Tango Therapeutics (Inst)
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); AstraZeneca (Inst); CellCentric (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunic Therapeutics (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MetaCurUm (Inst); MorphoSys (Inst); Myricx (Inst); Nurix (Inst); Oncternal Therapeutics (Inst); Orion (Inst); Pfizer (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Halda Therapeutics; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Jon Zugazagoitia
Honoraria - AstraZeneca Spain; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Guardant Health; Johnson & Johnson/Janssen; NanoString Technologies; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim Spain; Bristol-Myers Squibb/Celgene; Guardant Health; Johnson & Johnson/Janssen; Merck Serono; Novartis; Novartis; Pfizer; Pierre Fabre; Sanofi/Regeneron
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Guardant Health; MSD Oncology; NanoString Technologies; Pfizer; Pierre Fabre; Roche; Takeda
Research Funding - AstraZeneca (Inst); Johnson & Johnson/Janssen (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim Spain; Bristol-Myers Squibb/Celgene; Janssen Oncology; Pfizer; Roche/Genentech; Sanofi
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Katriina Jalkanen
Employment - Faron Pharmaceuticals (I)
Stock and Other Ownership Interests - Curify Labs; Faron Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Bayer (Inst); Lilly (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Panu Jaakkola
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; MSD
Research Funding - MSD (Inst)
 
Julia Lostes
Consulting or Advisory Role - Bristol-Myers Squibb; Medarex
Speakers' Bureau - Bristol-Myers Squibb; Medarex; Novartis
Research Funding - Corbus Pharmaceuticals (Inst); Daiichi Sankyo Europe GmbH (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medarex; Novartis; Pierre Fabre
 
David Vicente
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead/Forty Seven; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca
 
Farshid Dayyani
Consulting or Advisory Role - AstraZeneca; Eisai; Jazz Pharmaceuticals
Speakers' Bureau - Astellas Pharma; beone; ipsen; Sirtex Medical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Sarah Danson
Consulting or Advisory Role - Greywolf Therapeutics; Oxcia
Research Funding - Amgen (Inst); MSD Oncology (Inst); Orion (Inst); Scancell (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Mrinal Gounder
Honoraria - Gerson Lehrman Group; Great Debates and Updates; Guidepoint Global; Med Learning Group; Medscape; MJH/PER; OncLive/MJH Life Sciences; Research to Practice
Consulting or Advisory Role - AADi; Ayala Pharmaceuticals; Epizyme; Ikena Oncology; Immunome; Kura Oncology; Orion Health; Rain Therapeutics; SpringWorks Therapeutics
Research Funding - AADi (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Erasca, Inc (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Ikena Oncology (Inst); Kymera (Inst); Orion Health; Rain Oncology (Inst); Regeneron (Inst); SERVIER (Inst); SpringWorks Therapeutics (Inst); Tango Therapeutics (Inst); Vivace Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Foundation Medicine
 
Jussi Koivunen
Employment - Faron Pharmaceuticals
Honoraria - Amgen; AstraZeneca/MedImmune; BMS; Boehringer Ingelheim; Merck; Merck KGaA; Novartis; Pfizer; Roche; Siemens Healthineers
Research Funding - AstraZeneca/MedImmune (Inst); Roche (Inst)
Expert Testimony - Roche
 
Nicolas Penel
Honoraria - Astellas Pharma (Inst); MSD (Inst)
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera
Other Relationship - PharmaMar
 
Martino Pedrani
Travel, Accommodations, Expenses - Bayer
 
Steph A. Pang
Speakers' Bureau - Eisai
Travel, Accommodations, Expenses - Pfizer
 
Emma Rousi
Employment - Orion
 
Mikko Marttila
Employment - Orion
Stock and Other Ownership Interests - Orion (I)
 
Outi Erkkilä
Employment - Orion
Stock and Other Ownership Interests - Bioretec; Merck; Novo Nordisk; Orion; Pfizer; Sanofi; Teva
 
Chris Garratt
Employment - Orion
Stock and Other Ownership Interests - Orion
 
Ilaria Colombo
Employment - Medtronic (I)
Stock and Other Ownership Interests - Medtronic (I)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); BioNTech SE; Daiichi Sankyo Europe GmbH (I); GlaxoSmithKline (Inst); Incyte (Inst); MSD Oncology (Inst)
Speakers' Bureau - Abbvie (Inst); Daiichi Sankyo Europe GmbH (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst)
Research Funding - Debiopharm Group (Inst); Debiopharm Group (Inst); Incyte (Inst); Merck KGaA (Inst); MSD (Inst); Oasmia Pharmaceutical AB (Inst); Orion Clinical (Inst); PharmaMar (Inst); Tolremo (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline